GLONGHUI SEPTEMBER 25丨Dongyang Changjiang Pharmaceutical Co., Ltd. (01558.HK) announcement,The company's independent research and development product, protein human insulin mixed injection (30R) (“this product”), has been approved by the China State Drug Administration and approved for listing.

This product is a premixed insulin product used to treat diabetes. It is composed of 30% soluble human insulin and 70% protein human insulin. This product is suitable for the treatment of diabetes. It is injected subcutaneously. It has the characteristics of low incidence of hypoglycemia and good safety. It can effectively control postprandial blood sugar, fasting blood sugar, and glycated hemoglobin (HbA1c) levels. According to Ames China data, the sales amount of drugs in the diabetes sector in China in 2022 was about US$4.84 billion. Of these, domestic sales of insulin and its analogues in 2022 accounted for about 39.5% of the total sales value of the drug market in the diabetes sector, which has considerable market potential.

This product is a biological drug approved for marketing by the Group. The total R&D investment is approximately RMB 130.1 million. Furthermore, the Group has been deeply involved in the field of diabetes treatment for a long time, has comprehensive product plans, and has laid out a complete product line. The product was successfully approved for listing, which is beneficial to expanding the Group's business in the field of endocrine and metabolic treatment, and further enriches the Group's product portfolio.

bookThe announcement is a voluntary announcement issued by the company. The purpose is to enable investors to understand the Group's latest business developments. It does not include advertisements or intentions regarding the use of any drugs, surgical equipment, treatments or oral products.